Crizotinib (Xalkori) and
trametinib (Mekinist) have both
been listed on the Pharmaceutical
Benefits Scheme via a Managed
Entry Scheme (MES).
An MES provides “a means by
which to address the uncertainty
over the clinical benefit of a
medicine while providing early
access to those patients for whom
there is a high clinical need,” the
Health Department said.
Prescribers and patients are
advised that if the drugs do not
prove as beneficial in practice as
in clinical data presented to the
PBAC, they may have their listings
modified, or they may be removed
from the PBS.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Aug 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Aug 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.